Skip to content
Research Article Open access CC BY 4.0

Development and Validation of HPLC Method for the Quantification of Impending Genotoxic Impurities in Dapson Drug Substances

Haresh B. Patel, Rohit H. Dave, Sandip Vadariya, Hitin Hirpara, Trushar Patel

Biotechnology Journal International · pp. 1–17 · Published 22 Jun 2024

10.9734/bji/2024/v28i4724

Abstract

The assessment of toxicological concentrations of possible genotoxic contaminants in drug substances was regarded as an important and challenging discipline . The International Conference and Harmonization (ICH) recommended that most pharmaceutical products be allowed to include 1.5 μg/day of a genotoxic contaminant.  The goal  study was to develop a quick and accurate HPLC method for measuring potential genotoxic impurities (PGIs) in Dapson drug substances. The chromatographic conditions were appropriately optimized with the Phosphate and Acetate buffer on C18 & C8 columns to achieve a decent separation and response of each impurities peak with the Dapsone. A C8 column has been used with Phosphate buffer with the linear gradient combination with Acetonitrile as mobile phase and multiple wavelengths used based on UV maxima of respective impurity. According to International conference of Harmonization (ICH) criteria for the quantification of each impurity, method validation for HPLC was carried out regarding specificity, the limit of detection (LOD), the limit of quantification (LOQ), linearity, accuracy (recovery), precision, and solution stability. Three separate batches of Dapsone were successfully subjected to the desired procedures for the Genotoxic (GTI) determination and found not detected.  The corelation coefficient observed > 0.99 in linearity and 70% to 130% recovery observed in the accuracy during method validation hence method can be considered linear and accurate and can be used for testing of genotoxic impurity in Dapsone drug substances.

Genotoxic impurities HPLC analysis dapsone method development method validation dapson drug

References (12)

  1. 1 NTRK fusion-positive cancers and TRK inhibitor therapy [DOI]
  2. 2 Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials [DOI]
  3. 3 Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins [DOI]
  4. 4 The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development [DOI]
  5. 5 Stability‐indicating RP‐HPLC method development and validation for determination of nine impurities in apixaban tablet dosage forms. Robustness study by quality by design approach [DOI]
  6. 6 Recent Advances in the Impurity Profiling of Drugs [DOI]
  7. 7 Analysis of potential genotoxic impurities in pharmaceuticals by two-dimensional gas chromatography with Deans switching and independent column temperature control using a low-thermal-mass oven module [DOI]
  8. 8 Development and Validation of a Method for Simultaneous Estimation of Bupropion and Dextromethorphan Using Reverse Phase High Performance Liquid Chromatography in Active Pharmaceutical Ingredient Form [DOI]
  9. 9 Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Larotrectinib in its Formulations [DOI]
  10. 10 Development and Validation of Class I Preparation and Restoration Quality Assessment Methods [DOI]
  11. 11 Validated HPLC Method for Quantification of a Novel Trk Inhibitor, Larotrectinib in Mice Plasma: Application to a Pharmacokinetic Study [DOI]
  12. 12 Identification and characterization of unknown degradation product of larotrectinib sulphate [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

38

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.